Research and innovationEVOTEC's Campus Curie
In Toulouse, Evotec’s "Campus Curie" brings new momentum to biotech sector.
Evotec, a drug discovery and research specialist based in Toulouse since 2015, announced this past July its acquisition of Sanofi's Biopark, henceforth called "Campus Curie". In 5 years, Evotec has tripled its workforce and now employs 600 people on site. The company continues to show its ambitions in the pursuit of long-term growth of its activities. Evotec has been supported by Invest in Toulouse, which has accompanied them throughout their several phases of settling into the Pink City.
Focus on the new Campus Curie
Evotec is a global group headquartered in Hamburg. Listed on the stock exchange, the group has several subsidiaries on different continents (North America and Europe).
Within the framework of a strategic alliance with Sanofi, which includes the takeover by Evotec of the pharmaceutical group's R&D activities within Toulouse’s Oncopole, the latter was set up in the Biopark in 2015. Main occupant of the site, still managed by Sanofi, Evotec's new subsidiary built up a solid network of local and international partners between 2015 and 2020. Most of its turnover comes from international markets (50% of Evotec's turnover in Toulouse comes from the USA).
After developing numerous projects and increasing its workforce to 600 employees, the company announced in July 2020 the acquisition of Sanofi's Biopark, now called "Campus Curie".
The purpose of this acquisition is to enable Evotec to significantly expand its existing capacities while retaining maximum flexibility to build projects over the long term. Evotec is already actively recruiting for more than 200 jobs, most of them with high added value, which will be created in the next two years.
« The acquisition of Campus Curie is a strong commitment for us and a sign of confidence in the Toulouse teams. We benefit from a privileged environment here: we have access to highly qualified personnel, the region's scientific ecosystem is dynamic and varied, and the quality of the site and services is excellent. We will be able to support our development on a solid and proven basis. The biotech sector is booming, both here and around the world, and we should see great growth in the years to come. »
- explains Craig Johnstone, President of Evotec France and Chief Operating Officer of the Group.
Invest in Toulouse, close synergy with Evotec
Evotec’s acquisition of the site located in the heart of the Campus Santé du Futur (formerly known as the Oncopole) is excellent news. In addition to illustrating the excellence of the biotech sector and the quality of the skills of an interdisciplinary scientific community, this investment will help to strengthen the visibility of innovative initiatives. This is the best way to ensure that the promising ecosystem will become better known and more attractive.
« The Invest in Toulouse team has been working for several years with Evotec. We have notably facilitated their set-up in Toulouse and we regularly organize, in their presence, company visits. This collaboration is precious to us, because the dynamism of this sector contributes to the attractiveness of the city. Their success is an example and their feedback is very useful for companies looking for a new city in which to set up.»
- emphasizes Silvia Ferrari, Director of Invest in Toulouse.
Health Campus of the Future
A place of care, an international research center and an innovation platform, the site brings together public and private forces in the health and research sectors and favors transdisciplinarity. Already recognized for its excellence in oncology, the campus is now opening up to other areas of health in medicine of the future, such as aging, and is taking advantage of advances in artificial intelligence. Researchers, physicians, entrepreneurs, and more than 6,000 life sciences and health professionals work on the site, in 40 companies.